Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
5.27
-0.07 (-1.31%)
At close: Dec 12, 2025, 4:00 PM EST
5.32
+0.05 (0.95%)
After-hours: Dec 12, 2025, 7:59 PM EST
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -61.54% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-61.54%
P/S Ratio
27,494.22
Revenue / Employee
$339
Employees
59
Market Cap
549.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | - |
| Dec 31, 2022 | -68.00K | -4.48M | - |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
| Dec 31, 2018 | 10.33M | -365.65K | -3.42% |
| Dec 31, 2017 | 10.70M | 7.87M | 278.50% |
| Dec 31, 2016 | 2.83M | -7.81M | -73.44% |
| Dec 31, 2015 | 10.64M | 450.46K | 4.42% |
| Dec 31, 2014 | 10.19M | -7.72M | -43.11% |
| Dec 31, 2013 | 17.91M | -7.26M | -28.85% |
| Dec 31, 2012 | 25.18M | 909.61K | 3.75% |
| Dec 31, 2011 | 24.27M | 3.27M | 15.59% |
| Dec 31, 2010 | 20.99M | -6.56M | -23.80% |
| Dec 31, 2009 | 27.55M | -5.27M | -16.06% |
| Dec 31, 2008 | 32.82M | 18.20M | 124.43% |
| Dec 31, 2007 | 14.62M | 12.98M | 790.75% |
| Dec 31, 2006 | 1.64M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALT News
- 13 days ago - Altimmune Announces CEO Transition and Succession Plan - GlobeNewsWire
- 18 days ago - Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 23 days ago - Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Altimmune: Probing Pemvi's MASH Data - Seeking Alpha
- 4 weeks ago - Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 5 weeks ago - Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 5 weeks ago - Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Altimmune Announces Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire